Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.
Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.
Add Asianet Newsable as a Preferred Source
Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company stated.
Get updates to this developing story <directly on Stocktwits.<